FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334952610> ?p ?o ?g. }

• W2334952610 endingPage "687" @default.
• W2334952610 startingPage "687.2" @default.
• W2334952610 abstract "<h3>Background</h3> Mavrilimumab is a human monoclonal antibody targeting the alpha subunit of GM-CSF receptor and was recently evaluated in RA subjects in a phase 2a study (EARTH). Results reported from the European (EU) cohort demonstrated that mavrilimumab shows activity in subjects with moderate to severe RA (Burmester et al. 2013). Here, we describe final data from EARTH comparing results in the EU and Japanese (JA) cohorts. <h3>Objectives</h3> Biomarker (BM) assessments were performed to elucidate mechanistic aspects of mavrilimumab. <h3>Methods</h3> Mavrilimumab (10, 30, 50 or 100 mg) or placebo was administered SC every other week to subjects with moderate/severe RA (DAS28 >3.2) on stable methotrexate for 12 weeks followed by a 12 week drug free follow up period. A multi-biomarker disease activity (MBDA) score was calculated using the validated Vectra ®DA algorithm and used to track the effect of the drug on disease activity over time. An additional multi-BM-based algorithm (MBSD) was used to assess the impact of mavrilimumab on markers known to be associated with progressive joint damage. The relative ability of different mavrilimumab doses, over time, to saturate GM-CSF receptors in whole blood was examined by flow cytometry using receptor occupancy assay (ROA) in the EU cohorts. <h3>Results</h3> In the EARTH study, the primary endpoint (DAS28-CRP reduction ≥1.2 at Week 12) was met. Improvements were seen as early as week 2 and persisted through the 12 week follow up. The MBDA score decreased significantly as early as day 8 (p<0.05) and remained suppressed during the entire treatment period. Additional samples from the 100 mg EU cohort showed that suppression of the MBDA was maintained for a minimum of 4 weeks after the last dose. Individual components of the MBDA score, as well as additional BMs in the EU cohort showed that CRP, SAA, IL-6, IL-2RA and MDC were significantly decreased on days 8, 15, 88 and 113 in the 100 mg cohort compared to placebo. Lesser or no changes were observed with the 10 mg cohort. There was an early and sustained dose-related inhibition of the joint damage composite index MBSD observed in the EU cohort. In the JA cohort a significant decrease was also observed when comparing treatment group to placebo group. The ROA results showed the 10 mg dose was sub-optimal in its ability to saturate GM-CSF receptor. This sub-optimal effect was reflected in the BM analysis and in the clinical efficacy endpoints. <h3>Conclusions</h3> Promising results of mavrilimumab support further clinical development at doses greater than 10 mg. Mechanistically, the drug suppressed both acute phase and inflammatory blood markers. Tracking of disease activity by MBDA showed a clear biomarker-based dose-response relationship. The association of MBSD decline with radiographic damage will be assessed in an on-going phase 2b study. <h3>References</h3> Burmester GR, et al. 2013, ARD, 72 (9):1445-52. <h3>Disclosure of Interest</h3> W. White Shareholder of: AstraZeneca, Employee of: MedImmune, P. Ryan Shareholder of: AstraZeneca, Employee of: MedImmune, X. Guo Shareholder of: AstraZeneca, Employee of: MedImmune, D. Sinibaldi Shareholder of: AstraZeneca, Employee of: MedImmune, G. Ranganna Shareholder of: AstraZeneca, Employee of: MedImmune, A. Godwood Shareholder of: AstraZeneca, Employee of: MedImmune, D. Saurigny Shareholder of: AstraZeneca, Employee of: MedImmune, D. Close Shareholder of: AstraZeneca, Employee of: MedImmune, S. Eck Shareholder of: AstraZeneca, Employee of: MedImmune, D. Wilkins Shareholder of: AstraZeneca, Employee of: MedImmune, L. Roskos Shareholder of: AstraZeneca, Employee of: MedImmune, M. Sleeman Shareholder of: AstraZeneca, Employee of: MedImmune, W. Li Shareholder of: Crescendo Bioscience, Employee of: Crescendo Bioscience, G. Cavet Shareholder of: Crescendo Bioscience, Employee of: Crescendo Bioscience, N. Defranoux Shareholder of: Crescendo Bioscience, Employee of: Crescendo Bioscience <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5731" @default.
• W2334952610 created "2016-06-24" @default.
• W2334952610 creator A5011433734 @default.
• W2334952610 creator A5012639509 @default.
• W2334952610 creator A5018194397 @default.
• W2334952610 creator A5025909380 @default.
• W2334952610 creator A5028403747 @default.
• W2334952610 creator A5045509731 @default.
• W2334952610 creator A5052629023 @default.
• W2334952610 creator A5054978978 @default.
• W2334952610 creator A5061314442 @default.
• W2334952610 creator A5064255618 @default.
• W2334952610 creator A5066975328 @default.
• W2334952610 creator A5069627913 @default.
• W2334952610 creator A5074711841 @default.
• W2334952610 creator A5084415784 @default.
• W2334952610 creator A5086610054 @default.
• W2334952610 date "2014-06-01" @default.
• W2334952610 modified "2023-09-27" @default.
• W2334952610 title "SAT0260 Biomarkers Associated with Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate with Changes in Clinical Response in Subjects Treated with Mavrilimumab at Doses above 10 Mg" @default.
• W2334952610 doi "https://doi.org/10.1136/annrheumdis-2014-eular.5731" @default.
• W2334952610 hasPublicationYear "2014" @default.
• W2334952610 type Work @default.
• W2334952610 sameAs 2334952610 @default.
• W2334952610 citedByCount "0" @default.
• W2334952610 crossrefType "journal-article" @default.
• W2334952610 hasAuthorship W2334952610A5011433734 @default.
• W2334952610 hasAuthorship W2334952610A5012639509 @default.
• W2334952610 hasAuthorship W2334952610A5018194397 @default.
• W2334952610 hasAuthorship W2334952610A5025909380 @default.
• W2334952610 hasAuthorship W2334952610A5028403747 @default.
• W2334952610 hasAuthorship W2334952610A5045509731 @default.
• W2334952610 hasAuthorship W2334952610A5052629023 @default.
• W2334952610 hasAuthorship W2334952610A5054978978 @default.
• W2334952610 hasAuthorship W2334952610A5061314442 @default.
• W2334952610 hasAuthorship W2334952610A5064255618 @default.
• W2334952610 hasAuthorship W2334952610A5066975328 @default.
• W2334952610 hasAuthorship W2334952610A5069627913 @default.
• W2334952610 hasAuthorship W2334952610A5074711841 @default.
• W2334952610 hasAuthorship W2334952610A5084415784 @default.
• W2334952610 hasAuthorship W2334952610A5086610054 @default.
• W2334952610 hasConcept C126322002 @default.
• W2334952610 hasConcept C142724271 @default.
• W2334952610 hasConcept C185592680 @default.
• W2334952610 hasConcept C203014093 @default.
• W2334952610 hasConcept C203092338 @default.
• W2334952610 hasConcept C204787440 @default.
• W2334952610 hasConcept C27081682 @default.
• W2334952610 hasConcept C2777575956 @default.
• W2334952610 hasConcept C2781059491 @default.
• W2334952610 hasConcept C2781197716 @default.
• W2334952610 hasConcept C535046627 @default.
• W2334952610 hasConcept C55493867 @default.
• W2334952610 hasConcept C71924100 @default.
• W2334952610 hasConcept C72563966 @default.
• W2334952610 hasConcept C90924648 @default.
• W2334952610 hasConceptScore W2334952610C126322002 @default.
• W2334952610 hasConceptScore W2334952610C142724271 @default.
• W2334952610 hasConceptScore W2334952610C185592680 @default.
• W2334952610 hasConceptScore W2334952610C203014093 @default.
• W2334952610 hasConceptScore W2334952610C203092338 @default.
• W2334952610 hasConceptScore W2334952610C204787440 @default.
• W2334952610 hasConceptScore W2334952610C27081682 @default.
• W2334952610 hasConceptScore W2334952610C2777575956 @default.
• W2334952610 hasConceptScore W2334952610C2781059491 @default.
• W2334952610 hasConceptScore W2334952610C2781197716 @default.
• W2334952610 hasConceptScore W2334952610C535046627 @default.
• W2334952610 hasConceptScore W2334952610C55493867 @default.
• W2334952610 hasConceptScore W2334952610C71924100 @default.
• W2334952610 hasConceptScore W2334952610C72563966 @default.
• W2334952610 hasConceptScore W2334952610C90924648 @default.
• W2334952610 hasIssue "Suppl 2" @default.
• W2334952610 hasLocation W23349526101 @default.
• W2334952610 hasOpenAccess W2334952610 @default.
• W2334952610 hasPrimaryLocation W23349526101 @default.
• W2334952610 hasRelatedWork W1977601919 @default.
• W2334952610 hasRelatedWork W2159713565 @default.
• W2334952610 hasRelatedWork W2401514108 @default.
• W2334952610 hasRelatedWork W2414220780 @default.
• W2334952610 hasRelatedWork W2775812515 @default.
• W2334952610 hasRelatedWork W2783466784 @default.
• W2334952610 hasRelatedWork W2806179142 @default.
• W2334952610 hasRelatedWork W2810108657 @default.
• W2334952610 hasRelatedWork W2995476051 @default.
• W2334952610 hasRelatedWork W70445611 @default.
• W2334952610 hasVolume "73" @default.
• W2334952610 isParatext "false" @default.
• W2334952610 isRetracted "false" @default.
• W2334952610 magId "2334952610" @default.
• W2334952610 workType "article" @default.